EHS
EHS

Verve begins human tests of first ‘base editor,’ aiming at heart disease



Somewhere in New Zealand, the first patient ever has been dosed with a kind of gene-editing treatment known as a base editor, a newer way of utilizing CRISPR for gene editing. The company studying the treatment, Verve Therapeutics, announced the news Tuesday.

The treatment is aimed at a relatively common form of high cholesterol that affects millions of people, a very different population than those normally treated with gene therapies. Eventually, Verve hopes that the treatment might be offered to people who have recently suffered heart attacks, or for other more common diseases.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED





Source link

EHS
Back to top button